成都康弘药业集团股份有限公司 2023年度独立董事述职报告 2023 年度，本人作为成都康弘药业集团股份有限公司（以下简 称"公司"）的独立董事，严格按照《公司法》《上市公司治理准则》 《上市公司独立董事管理办法》等有关法律法规，以及公司《独立董 事制度》《公司章程》的规定和要求开展工作，忠实履行职责，积极 出席相关会议，认真审议董事会各项议案，充分发挥了独立董事的作 用，较好地维护了社会公众股股东的合法权益。现将 2023 年的工作 情况简要汇报如下： 一、独立董事的基本情况 许楠，1987 年 5 月出生，中国国籍，澳大利亚居留权，毕业于 西南财经大学财务管理专业，博士研究生学历。现任西南财经大学会 计学院财务系教授、博士生导师，审计监察与风险防控研究中心学术 专家，公司独立董事。入选中国审计署联合国审计人才库，四川省成 都市工业和信息化专家库、西南财经大学光华英才工程（百人计划学 术类）等。 报告期内，本人作为公司独立董事任职符合《上市公司独立董事 管理办法》第六条规定的独立性要求，不存在影响独立性的情况。 二、独立董事年度履职概况 1、出席股东大会和董事会情况 | 独立董事 | | | 出席董事会会议 ...

一、独立董事的基本情况 邓宏光，1977 年 10 月出生，中国国籍，无境外居留权，法学博 士、博士后，西南政法大学民商法学院教授、博士生导师，现担任西 南政法大学知识产权研究中心副主任，重庆知识产权保护协同创新中 心副主任，中国知识产权法学研究会理事，公司独立董事，荣获商务 部海外知识产权维权专家称号、第二届全国知识产权领军人才等。 报告期内，本人作为公司独立董事任职符合《上市公司独立董事 管理办法》第六条规定的独立性要求，不存在影响独立性的情况。 成都康弘药业集团股份有限公司 2023年度独立董事述职报告 2023 年度，本人作为成都康弘药业集团股份有限公司（以下简 称"公司"）的独立董事，严格按照《公司法》《上市公司治理准则》 《上市公司独立董事管理办法》等有关法律法规，以及公司《独立董 事制度》《公司章程》的规定和要求开展工作，忠实履行职责，积极 出席相关会议，认真审议董事会各项议案，充分发挥了独立董事的作 用，较好地维护了社会公众股股东的合法权益。现将 2023 年的工作 情况简要汇报如下： | | | | 出席董事会会议情况 | | 出席股东大会会议情况 | | | --- | --- | --- ...

成都康弘药业集团股份有限公司 2023 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-4 | | 公司财务报表 | | | - 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-91 | () T () 事务所 北京市东城区朝阳门北大街 审计报告 XYZH/2024CDAA5B0049 成都康弘药业集团股份有限公司 成都康弘药业集团股份有限公司全体股东: 一、审计意见 我们审计了成都康弘药业集团股份有限公司(以下简称康弘药业公司)财务报表, 包括 2023年12月31日的合并及母公司资产负债表,2023年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表,以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反 映了康弘药业公司 2023年12月 ...

成都康弘药业集团股份有限公司 2023 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | 页码 | | --- | --- | | 鉴证报告 | 1-2 | | 关于募集资金 2023 年度存放与使用情况的专项报告 | 1-12 | ( ( Ci ( i ic (1 it C l | 信 永 中 和 会 计师 寓 条 所 北 京 市 东 城区 朝 阳 门 北 大 街 联系电话: +86 (010) 6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A. Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | 传臭: +86 (010) 6554 7190 | | Dongcheng District, Beijing, | | | | certified public accountants 100027, P.R. China | | facsimile: +86 (010) 6554 ...

Financial Performance - The cash inflow from operating activities increased to ¥4,352,805,943.42, up from ¥3,835,123,001.12, representing a growth of approximately 13.5%[6] - The net cash flow from operating activities reached ¥1,218,411,128.75, compared to ¥925,153,384.75 in the previous year, indicating a year-over-year increase of about 31.7%[6] - The total revenue from sales of goods and services was ¥4,271,777,412.23, compared to ¥3,691,535,938.52, marking an increase of approximately 15.7%[6] - The company reported a net profit of CNY 2,226,354,329.15 for the year[18] - The company's operating revenue for 2023 reached ¥3,957,459,641.68, representing a year-over-year increase of 16.77% from ¥3,389,028,158.63 in 2022[104] - Net profit attributable to shareholders for 2023 was ¥1,044,765,761.76, up 16.52% compared to ¥896,670,032.77 in 2022[104] - The net profit after deducting non-recurring gains and losses was ¥1,014,208,451.05, reflecting a 22.85% increase from ¥825,537,109.68 in the previous year[104] Cash Flow - Cash inflow from investment activities totaled ¥4,722,930,488.72, down from ¥5,833,063,790.53, reflecting a decrease of approximately 19%[6] - The net cash flow from investment activities was ¥6,616,219.22, a significant improvement from a negative cash flow of ¥215,552,978.73 in the previous year[6] - Cash inflow from financing activities was ¥9,412,344.00, a decrease from ¥20,695,003.00, representing a decline of about 54.5%[6] - The total cash outflow from operating activities was ¥3,134,394,814.67, compared to ¥2,909,969,616.37, indicating an increase of approximately 7.7%[6] - The cash received from tax refunds was ¥30,519,706.74, down from ¥65,959,584.91, showing a decrease of about 53.8%[6] - The cash paid for taxes was ¥422,039,016.27, slightly up from ¥409,715,735.63, representing an increase of approximately 3%[6] Assets and Equity - The total assets at the end of the period amount to CNY 5,908,418,872.53[18] - The total equity attributable to owners is CNY 5,680,957,236.72[18] - The company's registered and paid-in capital as of December 31, 2023, is CNY 919,463,954.00[22] - The net assets attributable to shareholders reached ¥7,804,029,406.63, up 13.07% from ¥6,901,806,830.70 in 2022[104] Research and Development - The company’s R&D investment amounted to CNY 452.48 million, up 4.02% from CNY 435.01 million in 2022[133] - The R&D investment accounted for 11.43% of operating revenue, down from 12.84% in the previous year[133] - The company continues to focus on expanding its product offerings in key therapeutic areas, including hypertension and diabetes, while investing in new product development[139] - The company is currently in the II phase of clinical trials for KH110-R01, aimed at treating mild to moderate Alzheimer's disease, which is expected to enhance its competitiveness in the neurology treatment field[157] - The company has several products in various stages of clinical trials, including KH801-R01 for tumors, which is in the IND application stage, expected to receive approval in March 2024[180] Governance and Management - The company has not reported any significant changes in the management team during the reporting period[63] - The company held its annual general meeting on May 23, 2023, with a participation rate of 65.95%[57] - The company held its first extraordinary general meeting of 2023 on August 3, 2023, with a participation rate of 69.57%[57] - The company held its second extraordinary general meeting of 2023 on December 22, 2023, with a participation rate of 66.84%[57] - The chairman of the board, Ke Zunhong, has held his position since February 5, 2001, and will serve until August 3, 2026[59] - Director Ke Xiao increased his shareholding by 3,499,998 shares during the reporting period, bringing his total to 80,259,998 shares[59] Market and Product Development - The company is focusing on expanding its market presence and enhancing product development strategies[66] - The company has emphasized its commitment to social responsibility and environmental sustainability in its operations[70] - The company is actively pursuing new product and technology development to stay competitive in the market[66] - The company’s KH631 eye injection project was included in the 2023 National Key R&D Program, which is expected to enhance sales growth and long-term operational development[119] - The company received approval for high-dose KH631 eye injection clinical trials, aimed at treating vision impairment due to diabetic macular edema, which is anticipated to improve patient compliance and reduce medical burdens[120] Financial Compliance and Reporting - The company’s financial statements comply with the accounting standards and accurately reflect its financial position as of December 31, 2023[26] - The financial report has been confirmed as accurate and complete by the company's legal representative and accounting heads[68] - The board of directors has been fully present for the review of the financial report, ensuring governance compliance[68] - The company has no significant discrepancies between financial reports prepared under domestic and international accounting standards[81] Strategic Initiatives - The company has made significant changes to its marketing strategy, leading to the termination of several projects, including the expansion of the traditional Chinese medicine production line and the marketing service network construction project[195] - The company is focusing on the consistency evaluation of generic drugs, which is crucial for compliance with national regulations[195] - The company has identified a significant market risk in the traditional Chinese medicine sector, leading to a strategic shift in project implementation[195] - The company plans to change the use of remaining raised funds totaling 45.2793 million yuan for other urgent investment projects to enhance the efficiency of fund utilization[196]

Financial Performance - The company's operating revenue for Q1 2024 reached ¥1,092,784,087.91, representing a 23.50% increase compared to ¥884,838,651.01 in the same period last year[4] - Net profit attributable to shareholders was ¥373,521,473.06, up 33.72% from ¥279,331,041.04 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥362,972,028.39, reflecting a 36.18% increase from ¥266,531,188.33 in the previous year[4] - Basic and diluted earnings per share were both ¥0.41, up 36.67% from ¥0.30 in the previous year[4] - The company reported a gross profit margin of approximately 39.7%, compared to 36.2% in the previous year[28] Cash Flow and Liquidity - The net cash flow from operating activities was ¥405,935,869.60, a significant increase of 116.28% compared to ¥187,686,073.46 in the same quarter last year[4] - Cash and cash equivalents decreased to ¥3,112,962,184.64 from ¥4,702,142,704.60, a decline of 33.8%[24] - The company reported a net decrease in cash and cash equivalents of $1,597,428,914.87, compared to a decrease of $1,453,163,182.48 in the previous period[31] - The ending balance of cash and cash equivalents was $3,072,565,305.73, an increase from $2,122,513,089.46 in the previous period[31] - Cash paid to employees increased to $333,991,570.88 from $275,502,890.22, reflecting a rise of 21.2%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,833,348,358.09, a 3.56% increase from ¥8,529,680,910.70 at the end of the previous year[4] - Total liabilities and equity amounted to ¥8,833,348,358.09, indicating a rise from ¥8,529,680,910.70[27] - Current liabilities decreased to ¥594,495,406.58 from ¥654,431,822.37, a reduction of about 9.16%[42] - Non-current liabilities decreased to ¥55,481,924.54 from ¥63,332,040.04, reflecting a decline of approximately 12.66%[42] - The company reported a significant reduction in accounts payable from ¥344,029,888.60 to ¥255,973,214.44, a decrease of about 25.6%[42] Segment Performance - The pharmaceutical manufacturing segment contributed ¥109,253.40 million, accounting for 99.98% of total revenue, with a year-on-year growth of 23.48%[4] - The biological medicine segment saw a significant increase of 59.00%, contributing ¥54,274.38 million, which is 49.67% of total revenue[4] Research and Development - Research and development expenses were ¥63,845,609.61, slightly down from ¥68,663,415.81 in Q1 2023[28] - The company continues to focus on research and development of new products and technologies to enhance market expansion strategies[43] Accounting and Standards - The company is set to implement new accounting standards starting in 2024, which may impact financial reporting[49]

成都康弘药业集团股份有限公司董事会 2024 年 4 月 24 日 根据《上市公司独立董事管理办法》的规定，独立董事应当每年 对独立性情况进行自查，并将自查情况提交董事会。董事会应当每年 对在任独立董事独立性情况进行评估并出具专项意见，与年度报告同 时披露。基于此，成都康弘药业集团股份有限公司（以下简称"公司"） 董事会，就公司在任独立董事的独立性情况进行评估并出具如下专项 意见： 根据公司独立董事自查及其在公司的履职情况，董事会认为公司 独立董事均能够胜任独立董事的职责要求，其未在公司担任除独立董 事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司 以及主要股东之间不存在妨碍我们进行独立客观判断的关系，不存在 影响独立董事独立性的情况，符合《上市公司独立董事管理办法》等 法律法规及《公司章程》中关于独立董事的任职资格及独立性的相关 要求。 成都康弘药业集团股份有限公司 董事会关于独立董事独立性自查情况的专项意见 ...

证券代码：002773 证券简称：康弘药业 公告编号：2024-011 成都康弘药业集团股份有限公司 第八届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届监 事会第六次会议于 2024 年 4 月 24 日在公司会议室以现场方式召开。 会议通知于 2024 年 4 月 14 日以书面、传真或电子邮件等形式向所有 监事发出。本次监事会应到监事 3 名，实到监事 3 名，会议由监事会 主席龚文贤主持。符合《中华人民共和国公司法》和《成都康弘药业 集团股份有限公司章程》的有关规定。 二、监事会会议审议情况 会议以书面记名投票方式通过了如下决议： 1. 会议以3票同意，0票反对，0票弃权审议通过了《二○二三年 度监事会工作报告》。 监事会认为：本报告如实反映了二○二三年监事会的履职情况， 同意通过该报告，并表示将继续严格按照有关法律法规、监管要求及 《公司章程》的规定，恪尽职守，勤勉尽责，进一步促进公司的规范 1 / 6 运作。 《二〇二三年度监事会工作报告》于2 ...

2023 年度 非经营性资金占用及其他关联资金往来的 成都康弘药业集团股份有限公司 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | | - C - C () ( C ( ( | 信 永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86(010)6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | | | +86 (010) 6554 7190 | Dongcheng District, Beijing, | 传真: | | certified public accountants 100027, P.R.China | | facsimile: +86 (010) 6554 7190 | 关于成都康弘药业集团股份有限公司 除对康弘 ...

成都康弘药业集团股份有限公司 二○二三年度监事会工作报告 二○二三年，成都康弘药业集团股份有限公司（以下简称"公 司"）监事会严格按照《公司法》《证券法》《公司章程》和《监事 会议事规则》的有关规定，本着恪尽职守、勤勉尽责的工作态度，依 法独立行使职权，认真履行监督、检查职能，对公司的依法运作、财 务状况、募集资金、对外担保、收购、出售资产、内部控制等进行了 全面检查、监督，较好地发挥监事会的监督职能，保障了公司股东、 特别是中小投资者的利益，促进了公司的规范运作。 一、监事会会议召开情况 二○二三年度，公司监事会共计召开了 6 次会议，具体情况如下： 1、第七届监事会第十六次会议于 2023 年 4 月 27 日召开，会议 审议通过了《二○二二年度监事会工作报告》《二○二二年度财务决 算报告》《二○二二年度报告及摘要》《二○二二年度利润分配预案》 《二○二二年度募集资金存放与使用情况的专项报告》《二○二二年 度内部控制自我评价报告》《关于关联方资金占用及对外担保情况的 专项报告》《二○二三年度财务预算报告》《二○二三年第一季度报 告全文》《关于公司会计政策变更的议案》。 2、第七届监事会第十七次会议于 20 ...